With the expanded indication, Fibryga becomes the first and only on-demand, virally inactivated, human plasma-derived fibrinogen concentrate approved for this indication.
FDA approves expanded indication of Octapharma’s Fibriga for patients with bleeding due to acquired fibrinogen deficiency
Leave a comment
